An interventional study of Orchid 035 DCB Catheter and POBA Catheter in Peripheral Artery Disease, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.
Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 22nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2019, is one of 34 with no phase, reaches primary completion later than 16 of the 33 other live ones, and was the 27th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–100 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
Sirius Therapeutics Co., Ltd. · Sites in China
Ages 18–75
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 167 across the 53 interventional studies, 254 across the 27 observational. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 80 have an industry lead sponsor. The 10 most frequent:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the lead sponsor of 165 studies on the registry; 73 are open to participants now.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Arterial Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
| NCT07397390The First Affiliated Hospital of Dalian Medical Universityan Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions | 2026-12-30 |
| NCT07602634Zhijun BaoRadiomics Features Predicting Outcomes of PAD | 2026-12-31 |
| NCT03791970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityStents Post-dilation With DCB or POBA in Femoropopliteal Arteries | 2026-12-31 |
| NCT07860138Fudan UniversityHemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 80 studies in Peripheral Arterial Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safety of stent angioplasty with Orchid 035 Drug Coated Dilatation (DCB) and Plain Old Balloon Angioplasty (POBA) for post-dilatation for long (>10cm) femoropopliteal chronic total occlusion.
A Prospective, Single Center, Case-cohort Study Using the Orchid Drug Coated Balloon for Post-Dilatation of the Stent for Treatment of Long Lesions in Femoropopliteal Arteries.
Patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should also be geographically stable, willing and able to cooperate in this clinical study and remain available for long-term follow-up. A patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful stent angioplasty for the occluded femoropopliteal arteries.
Prior to the index procedure the following tests and clinical data will be collected: informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of chronic limb ischemia (Rutherford category) and resting ankle-brachial index (ABI).
During the procedure, the vascular access can be achieved to the investigator's standard clinical practice. After successful lesion passage, diagnostic angiography of the lesion area and distal run-off is performed and angiographic measurements (vessel diameter, percentage stenosis and lesion length) are collected. All inflow-limiting lesion will be treated according to the investigators standard clinical practice before treatment of the target lesion. The study compares the efficacy and safety of stent angioplasty with Orchid 035 Drug Coated Dilatation (DCB) and Plain Old Balloon Angioplasty (POBA) for post-dilatation for long (>10cm) femoropopliteal chronic total occlusion. The indication for stent placement is based on the investigator's assessment. An expected total of 180 patients will be treated in the scope of this study. The lesion is located within the native superficial femoral artery and/or the popliteal artery. Prior to stents placement, pre-dilatation with the POBA balloon is mandatory. After stents placement, post-dilatation with the Orchid 035 DCB or POBA need to be performed. Patients will be invited for a follow-up visit at 1, 6 and 12 month post-procedure. The primary efficacy endpoint of the study is defined as the freedom from clinically-driven target lesion revascularization (TLR) at 12 months. Secondary endpoints include primary patency rate at 6 and 12 months, freedom from clinically-driven TLR at 6 months, clinical success at 1, 6 and 12 months and freedom from serious adverse events at pre-discharge, 1, 6 and 12 months follow-up.No other adjunctive therapies (atherectomy, laser) are allowed. The complete femoropopliteal vasculature should be treated in one single session, staged interventions are not allowed. All outflow-limiting lesions must be treated according to the hospital treatment standard.
The regular follow-ups are necessary to monitor the condition of the patient and the procedure. Patients will be invited for a follow-up visit at 1, 6 and 12 months after the index procedure. The following data will be collected during these follow-up visit: medication record, physical examination, rutherford categorization, ABI and color flow doppler ultrasound.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
Device: Orchid 035 DCB Catheter
POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
Device: POBA Catheter
Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
Primary patency rate
Absence of a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.5) at the target lesion and without TLR
Time frame: 12 months post-procedure
Freedom from clinically-driven TLR
TLR defined as a repeated intervention to maintain or re-establish patency within the region of the treated arteries
Time frame: 6 and 12 months post-procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Dec 2026, 95 months after the start.
Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 95 months is above that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University →